Skip to main content
Premium Trial:

Request an Annual Quote

Liotta/Petricoin Join Faculty of George Mason University; John West Heads Post-Merger Solexa; Genome Therapeutics Scientists Go to Genizon BioSciences; and Others

Lance Liotta and Emanuel Petricoin have been appointed to the faculty of George Mason University, the university said today. They are co-directors of the National Cancer Institute/Food and Drug Administration Clinical Proteomics Program.

 

Liotta is also chief of the laboratory of pathology at NCI's center for cancer research. He holds a medical degree from Case Western Reserve Medical School and a doctoral degree in biomedical engineering from CaseWestern ReserveUniversity. His appointment is effective May 15. 

 

Petricoin is also a senior investigator in the office of cell tissue and gene therapies in the center for biologics evaluation and research. He holds a doctorate in microbiology from the Universityof Marylandat College Park. He begins his appointment April 1.


 

Following the merger of Lynx Therapeutics and Solexa this week, John West, formerly Solexa's  chief executive, has become CEO of the combined company, also called Solexa. The board of the merged company will include members from both companies' boards. Craig Taylor, previously Lynx Therapeutics' chairman, will chair the new board.


 

Peter Fuller has become chief business officer of Cellular Genomics, a new position, the Branford, Conn.-based company said today. Prior to joining CGI, he was senior vice president for business development at Molecular Staging. Fuller holds PhD and MS degrees in biometrical genetics from the University of Nebraska and a BS from the California State University at Chico.


 

Thomas Theriault has become vice president of research at Genitope, the company said yesterday. He joins Genitope after nine years at Incyte, where he was most recently vice president of research. Prior to Incyte, Theriault co-founded Combion, a privately held DNA microarray company focused on genetic and genomic applications, where he also served as director of research until the company was acquired by Incyte in 1996. He holds a PhD in biophysical chemistry from StanfordUniversity and a BA in chemistry from DartmouthCollege.


 

Genizon BioSciences, formerly Galileo Genomics, has hired four former Genome Therapeutics scientists and promoted two of its own staff, the Montreal-based company said yesterday.

 

Tim Keith has joined the company as vice president and chief scientific officer. He is the former head of the human genetics group at Genome Therapeutics, now Oscient Pharmaceuticals. In addition, Randall Little has become executive director for computational biology, Paul Van Eerdewegh senior director for statistical genetics, and Jonathan Segal senior scientific software engineer for bioinformatics and statistical genetics.

 

Also, Majid Belouchi has been promoted to vice president and chief technology officer, and John Raelson to chief geneticist. Both are company founders.


 

David O'Reilly has become president of Catalyst Biosciences, the South San Francisco-based company said yesterday. He comes to Catalyst from Iconix Pharmaceuticals, where he was chief business officer. O' Reilly has a degree from WesleyanUniversityand received an MBA from Harvard Business School.


 

V.W. Brinkerhoff III has joined Gene Logic as senior vice president and general manager for its preclinical contract research business, the Gaithersburg, Md.-based company said on Monday. Prior to joining Gene Logic, he was group vice president for operations at Wilson Greatbatch Technologies. Earlier, he held senior management positions with Life Technologies, now Invitrogen.


 

Benitec said last week that Sally Brashears, the company's vice president of intellectual property, has been promoted to company secretary, according to an Australian stock exchange filing. She joined the company in 2004. Prior to that, she was with the patent law firm Moser, Patterson, and Sheridan. Before that, she served as director of intellectual property at Perlegen Sciences.

 

In addition, Benitec's chairman, Raymond Whitten, has been named alternate secretary.

 

Also, Ken Reed, Benitec's director of research and development, will retire from the company on March 15. He will remain as a non-executive director. Reed has been with Benitec since 2000.


 

Zach Hall has been appointed interim president of the California Institute for Regenerative Medicine, the funding agency for California's stem cell initiative, CIRM said last week. Most recently, he was director of the Zilkha Neurogenetic Institute at the University of Southern California and senior associate dean for academic development at the Keck School of Medicine of the University of Southern California.


 

Jeffrey Ross has become medical director of BioGenex Laboratories, the company said last week. He is a senior scientific fellow at Millennium Pharmaceuticals and chairman of pathology and laboratory medicine at the AlbanyMedicalCollege and AlbanyMedicalCenter. Ross holds degrees from OberlinCollegeand from the State University of New York at Buffalo School of Medicine. 


 

Jenniffer Collins has been promoted to principal accounting officer and principal financial officer of Orchid Biosciences, the company said in an SEC filing last week. She joined the company as corporate controller in March 2004. Collins holds a BSc degree in accounting from LehighUniversity.


 

Peter Amanatides will stand for election as a company director of Generex Biotechnology on April 5, the Toronto-based company said yesterday. He is the president and CEO of Pharmalogika, a consulting company for the pharmaceutical industry. From 1999 until 2002, he was directcor of quality systems for Celera Genomics. Amanatides holds an MS in biotechnology and molecular biology.


 

Richard Kniss will be appointed as non-executive chairman of Arcturus, the company said this week. He has been a board member since 2002. Kniss was senior vice president and general manager of the life science and chemical group of Agilent Technologies prior to his retirement in 2001.


 

Andrew Carr has become executive chairman of the board of Akubio, the Cambridge, UK-based company said on Monday. He replaces John Padfield, who stepped down as non-executive chairman to focus on other business commitments. Carr used to be CEO of Amersham Biosciences and director of Amersham.


 

Steven St. Peter has joined the supervisory board of Atugen, the Berlin-based company said last month. He is a partner of MPM Capital, an investor in Atugen, and an assistant clinical professor of medicine at ColumbiaUniversity. St. Peter holds a medical degree from WashingtonUniversity, an MBA from the Wharton School of the University of Pennsylvania, and a BA in chemistry from the Universityof Kansas.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.